Genetic Technologies Statistics
Total Valuation
GENE has a market cap or net worth of $6.04 million. The enterprise value is $3.81 million.
| Market Cap | 6.04M |
| Enterprise Value | 3.81M |
Important Dates
The next estimated earnings date is Tuesday, August 13, 2024, before market open.
| Earnings Date | Aug 13, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
GENE has 4.41 million shares outstanding.
| Shares Outstanding | 4.41M |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 1.33% |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.05 |
| Forward PS | n/a |
| PB Ratio | 1.88 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.66 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.67, with a Debt / Equity ratio of 0.08.
| Current Ratio | 1.67 |
| Quick Ratio | 1.42 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -480.22 |
Financial Efficiency
Return on equity (ROE) is -160.90% and return on invested capital (ROIC) is -285.91%.
| Return on Equity (ROE) | -160.90% |
| Return on Assets (ROA) | -105.50% |
| Return on Capital (ROIC) | -285.91% |
| Revenue Per Employee | $96,268 |
| Profits Per Employee | -$144,445 |
| Employee Count | 60 |
| Asset Turnover | 0.70 |
| Inventory Turnover | 10.79 |
Taxes
| Income Tax | -6,881 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -69.21% in the last 52 weeks. The beta is 0.44, so GENE's price volatility has been lower than the market average.
| Beta (5Y) | 0.44 |
| 52-Week Price Change | -69.21% |
| 50-Day Moving Average | 2.02 |
| 200-Day Moving Average | 2.70 |
| Relative Strength Index (RSI) | 27.97 |
| Average Volume (20 Days) | 69,571 |
Short Selling Information
| Short Interest | 76,321 |
| Short Previous Month | 126,150 |
| Short % of Shares Out | 3.32% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.68 |
Income Statement
In the last 12 months, GENE had revenue of $5.78 million and -$8.67 million in losses. Loss per share was -$3.04.
| Revenue | 5.78M |
| Gross Profit | 3.03M |
| Operating Income | -9.91M |
| Pretax Income | -8.51M |
| Net Income | -8.67M |
| EBITDA | n/a |
| EBIT | -8.49M |
| Loss Per Share | -$3.04 |
Balance Sheet
The company has $2.49 million in cash and $255,027 in debt, giving a net cash position of $2.23 million or $0.51 per share.
| Cash & Cash Equivalents | 2.49M |
| Total Debt | 255,027 |
| Net Cash | 2.23M |
| Net Cash Per Share | $0.51 |
| Equity (Book Value) | 3.21M |
| Book Value Per Share | 0.73 |
| Working Capital | 1.53M |
Cash Flow
In the last 12 months, operating cash flow was -$5.07 million and capital expenditures -$28,468, giving a free cash flow of -$5.10 million.
| Operating Cash Flow | -5.07M |
| Capital Expenditures | -28,468 |
| Free Cash Flow | -5.10M |
| FCF Per Share | -$26.51 |
Margins
Gross margin is 52.51%, with operating and profit margins of -171.51% and -150.04%.
| Gross Margin | 52.51% |
| Operating Margin | -171.51% |
| Pretax Margin | -147.25% |
| Profit Margin | -150.04% |
| EBITDA Margin | n/a |
| EBIT Margin | -146.94% |
| FCF Margin | -88.30% |
Dividends & Yields
GENE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -28.00% |
| Shareholder Yield | -28.00% |
| Earnings Yield | -143.54% |
| FCF Yield | -84.47% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on December 14, 2023. It was a reverse split with a ratio of 1:5.
| Last Split Date | Dec 14, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:5 |
Scores
GENE has an Altman Z-Score of -28.71 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -28.71 |
| Piotroski F-Score | 1 |